Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

NCT07339176 is registered in ClinicalTrials.gov with Onchilles Pharma Inc as lead sponsor.

NCT NCT07339176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07339176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
Lead sponsor
Onchilles Pharma Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 25, 2026
Completion date
November 30, 2029
Enrollment
275 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, triple-negative, carcinoma, non-small-cell lung, carcinoma, squamous cell, head and neck neoplasms, melanoma, neoplasms, solid tumor, squamous cell carcinoma of skin